Shaanxi Panlong Pharmaceutical Group Limited By Share Ltd Class A (002864) - Total Assets
Based on the latest financial reports, Shaanxi Panlong Pharmaceutical Group Limited By Share Ltd Class A (002864) holds total assets worth CN¥2.40 Billion CNY (≈ $351.35 Million USD) as of September 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. See what is Shaanxi Panlong Pharmaceutical Group Lim's book value for net asset value and shareholders' equity analysis.
Shaanxi Panlong Pharmaceutical Group Limited By Share Ltd Class A - Total Assets Trend (2013–2024)
This chart illustrates how Shaanxi Panlong Pharmaceutical Group Limited By Share Ltd Class A's total assets have evolved over time, based on quarterly financial data.
Shaanxi Panlong Pharmaceutical Group Limited By Share Ltd Class A - Asset Composition Analysis
Current Asset Composition (December 2024)
Shaanxi Panlong Pharmaceutical Group Limited By Share Ltd Class A's total assets of CN¥2.40 Billion consist of 77.7% current assets and 22.3% non-current assets.
| Asset Category | Amount (CNY) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | CN¥0.00 | 51.3% |
| Accounts Receivable | CN¥496.71 Million | 21.8% |
| Inventory | CN¥95.58 Million | 4.2% |
| Property, Plant & Equipment | CN¥0.00 | 0.0% |
| Intangible Assets | CN¥51.35 Million | 2.3% |
| Goodwill | CN¥0.00 | 0.0% |
Asset Composition Trend (2013–2024)
This chart illustrates how Shaanxi Panlong Pharmaceutical Group Limited By Share Ltd Class A's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see 002864 market cap.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Shaanxi Panlong Pharmaceutical Group Limited By Share Ltd Class A's current assets represent 77.7% of total assets in 2024, an increase from 64.5% in 2013.
- Cash Position: Cash and equivalents constituted 51.3% of total assets in 2024, up from 19.8% in 2013.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 2.0% of total assets, a decrease from 3.0% in 2013.
- Asset Diversification: The largest asset category is accounts receivable at 21.8% of total assets.
Shaanxi Panlong Pharmaceutical Group Limited By Share Ltd Class A Competitors by Total Assets
Key competitors of Shaanxi Panlong Pharmaceutical Group Limited By Share Ltd Class A based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Daihan Pharmaceutical Co.Ltd
KQ:023910
|
Korea | ₩344.02 Billion |
|
Aurobindo Pharma Limited
NSE:AUROPHARMA
|
India | Rs525.46 Billion |
|
China Resources Sanjiu Medical & Pharmaceutical Co Ltd
SHE:000999
|
China | CN¥56.56 Billion |
|
Ningbo Menovo Pharm Co Ltd
SHG:603538
|
China | CN¥4.75 Billion |
|
Zhejiang Xianju Pharmaceutical Co Ltd
SHE:002332
|
China | CN¥7.26 Billion |
|
Qianjiang Yongan Pharmaceutical Co Ltd
SHE:002365
|
China | CN¥2.26 Billion |
|
Zhejiang Cheng Yi Pharmaceutical Co Ltd
SHG:603811
|
China | CN¥1.69 Billion |
|
Hainan Honz Pharmaceutical Co
SHE:300086
|
China | CN¥1.88 Billion |
Shaanxi Panlong Pharmaceutical Group Limited By Share Ltd Class A - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 3.11 | 3.92 | 2.51 |
| Quick Ratio | 2.91 | 3.73 | 2.32 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | CN¥1.27 Billion | CN¥1.31 Billion | CN¥519.23 Million |
Shaanxi Panlong Pharmaceutical Group Limited By Share Ltd Class A - Advanced Valuation Insights
This section examines the relationship between Shaanxi Panlong Pharmaceutical Group Limited By Share Ltd Class A's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 2.37 |
| Latest Market Cap to Assets Ratio | 0.21 |
| Asset Growth Rate (YoY) | 7.3% |
| Total Assets | CN¥2.28 Billion |
| Market Capitalization | $470.30 Million USD |
Valuation Analysis
Below Book Valuation: The market values Shaanxi Panlong Pharmaceutical Group Limited By Share Ltd Class A's assets below their book value (0.21x), which may indicate investor concerns about asset quality or future growth.
Positive Asset Growth: Shaanxi Panlong Pharmaceutical Group Limited By Share Ltd Class A's assets grew by 7.3% over the past year, showing continued investment in the company's operational capacity.
Annual Total Assets for Shaanxi Panlong Pharmaceutical Group Limited By Share Ltd Class A (2013–2024)
The table below shows the annual total assets of Shaanxi Panlong Pharmaceutical Group Limited By Share Ltd Class A from 2013 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | CN¥2.28 Billion ≈ $333.64 Million |
+7.29% |
| 2023-12-31 | CN¥2.13 Billion ≈ $310.96 Million |
+10.06% |
| 2022-12-31 | CN¥1.93 Billion ≈ $282.53 Million |
+45.15% |
| 2021-12-31 | CN¥1.33 Billion ≈ $194.65 Million |
+14.42% |
| 2020-12-31 | CN¥1.16 Billion ≈ $170.12 Million |
+25.16% |
| 2019-12-31 | CN¥928.88 Million ≈ $135.92 Million |
+13.58% |
| 2018-12-31 | CN¥817.84 Million ≈ $119.68 Million |
+8.62% |
| 2017-12-31 | CN¥752.93 Million ≈ $110.18 Million |
+49.24% |
| 2016-12-31 | CN¥504.50 Million ≈ $73.82 Million |
+16.42% |
| 2015-12-31 | CN¥433.33 Million ≈ $63.41 Million |
+7.99% |
| 2014-12-31 | CN¥401.26 Million ≈ $58.72 Million |
+17.19% |
| 2013-12-31 | CN¥342.39 Million ≈ $50.10 Million |
-- |
About Shaanxi Panlong Pharmaceutical Group Limited By Share Ltd Class A
Shaanxi Panlong Pharmaceutical Group Limited By Share Ltd researches and develops, produces, and sells Chinese patent medicines in China. It offers orthopedic, cardiovascular, cerebrovascular, digestive, respiratory, pediatrics, gynecology, hepatobiliary, rheumatism and bone injury, tonic, heat-clearing and detoxifying, and liver and gallbladder drugs, as well as supplements and traditional Chine… Read more